Printer Friendly

VitaGen sponsoring air ambulance shuttle to patients with acute liver failure in artificial liver clinical trial.

VitaGen, Inc., La Jolla, CA, announced on June 7 that it will sponsor an air ambulance shuttle to transport Fulminant Hepatic Failure (FHF) patients for enrollment into an ongoing clinical trial using the ELAD Artificial Liver at the University of Chicago Hospitals. The ELAD Artificial Liver is an extracorporeal liver assist device designed to provide temporary hepatic replacement therapy for patients with FHF until their own liver can regenerate or sustain patients until a suitable organ becomes available.

The company says the ELAD Artificial Liver is the first investigational device to use human liver cells instead of porcine cells and is designed for continuous therapy for up to 10 days. Referring physicians should contact VitaGen for more information on patient enrollment into the clinical trial.

VitaGen initiated the second clinical trial to evaluate the safety of its ELAD Artificial Liver at the University of Chicago Hospitals in February.

Contact: Carol Conlin, RN - (619) 552-1522
COPYRIGHT 1999 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:VitaGen sponsoring air ambulance shuttle to patients with acute liver failure in artificial liver clinical trial.
Publication:Transplant News
Geographic Code:1USA
Date:Jun 14, 1999
Words:154
Previous Article:Ortec receives FDA approval to begin pivotal study of cultured skin product to close wounds of burn victims.
Next Article:Special offer extended for medical employment opportunities newsletter.
Topics:


Related Articles
Circe Biomedical receives FDA clearance to initiate multi-center trial of its HepatAssist Liver Support System
VitaGen begins 2nd clinical trial of artificial liver device.
Artificial liver using human cells keeps Illinois woman alive until organ found for transplant.
Pittsburgh researchers begin clinical trial with VitaGen bio-artificial liver assist device.
Nagasaki ethics committee oks artificial liver trial.
ARBIOS SYSTEMS ACQUIRES ASSETS FROM CIRCE BIOMEDICAL.
ARBIOS ANNOUNCES POSITIVE PRECLINICAL DATA FOR SEPET.
Vital Therapies acquires assets of VitaGen to continue development of liver assist device.
First patient enrolled in artificial liver device Phase I trial at Albert Einstein.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |